Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
1.
Article de Chinois | WPRIM | ID: wpr-936333

RÉSUMÉ

OBJECTIVE@#To construct a luciferase reporter gene vector carrying human nuclear factor of activated T cells 2 (NFATc2) gene promoter and examine the effects of metformin and lipopolysaccharide (LPS) on the transcriptional activity of NFATc2 gene.@*METHODS@#The promoter sequence of human NFATc2 gene was acquired from UCSC website for PCR amplification. NFATc2 promoter fragment was inserted into pGL3-basic plasmid double cleaved with Kpn Ⅰ and Hind Ⅲ. The resultant recombinant plasmid pGL3-NFATC2-promoter was co-transfected with the internal reference plasmid pRL-TK in 293F cells, and luciferase activity in the cells was detected. Reporter gene vectors of human NFATc2 gene promoter with different fragment lengths were also constructed and assayed for luciferase activity. The changes in transcription activity of NFATc2 gene were assessed after treatment with different concentrations of metformin and LPS for 24 h. We also examined the effect of mutation in RUNX2-binding site in NFATC2 gene promoter on the regulatory effects of metformin and LPS on NFATc2 transcription.@*RESULTS@#We successfully constructed pGL3-NFATc2-promoter plasmids carrying different lengths (2170 bp, 2077 bp, 1802 bp, 1651 bp, 1083 bp, 323 bp) of NFATc2 promoter sequences as verified by enzymatic digestion and sequencing. Transfection of 293F cells with the plasmid carrying a 1651 bp NFATc2 promoter (pGL3-1651 bp) resulted in the highest transcriptional activity of NFATc2 gene, and the luciferase activity was approximately 3.3 times that of pGL3-2170 bp (1.843 ± 0.146 vs 0.547 ± 0.085). Moderate (5 mmol/L) and high (10 mmol/L) concentrations of metformin significantly upregulated the transcriptional activity of pGL3-1651 bp by up to 2.5 and 3 folds, respectively. LPS at different doses also upregulated the transcriptional activity of pGL3-1651 bp by at least 1.6 folds. The mutation in the RUNX2 binding site on pGL3-1651 bp obviously reduced metformin- and LPS-induced enhancement of pGL3-1651bp transcription by 1.7 and 2 folds, respectively.@*CONCLUSION@#pGL3-NFATc2-promoter can be transcribed and activated in 293F cells, and LPS and metformin can activate the transcription of pGL3- NFATc2-promoter in a RUNX2-dependent manner.


Sujet(s)
Humains , Sous-unité alpha 1 du facteur CBF/génétique , Lipopolysaccharides/pharmacologie , Luciferases/génétique , Metformine/pharmacologie , Facteurs de transcription NFATC/génétique , Régions promotrices (génétique) , Lymphocytes T , Transcription génétique/effets des médicaments et des substances chimiques , Transfection
2.
Exp. mol. med ; Exp. mol. med;: 565-573, 2008.
Article de Anglais | WPRIM | ID: wpr-84645

RÉSUMÉ

Viral proteins of gamma-2 herpesviruses, such as LMP2A of Epstein Barr virus (EBV) and Tip of herpesvirus saimiri (HVS) dysregulate lymphocyte signaling by interacting with Src family kinases. K15 open reading frame of Kaposi's sarcoma associated herpesvirus (KSHV), located at the right end of the viral genome, encodes several splicing variants differing in numbers of transmembrane domains. Previously, we demonstrated that the cytoplasmic tail of the K15 protein interfered with B cell receptor signal transduction to cellular tyrosine phosphorylation and calcium mobilization. However, the detailed mechanism underlying this phenomenon was not understood. In the C-terminal cytoplasmic region of K15, putative binding domains for Src-SH2 and -SH3 were identified. In this study, we attempted to characterize these modular elements and cellular binding protein(s) by GST pull down and co-immunoprecipitation assays. These studies revealed that K15 interacted with the major B cell tyrosine kinase Lyn. In vitro kinase and transient co-expression assays showed that the expression of K15 protein resulted in activation of Lyn kinase activity. In addition, GST pull down assay suggested that the SH2 domain of Lyn alone was necessary for interaction with the C-terminal SH2B (YEEV) of K15, but the addition of Lyn SH3 to the SH2 domain increases the binding affinity to K15 protein. The data from luciferase assays indicate that K15 expression in BJAB cells induced NFAT and AP1 activities. The tyrosine residue in the C-terminal end of K15 required for the Lyn interaction appeared to be essential for NFAT/AP1 activation, highlighting the significance of the C-terminal SH2B of K15 as a modular element in interfering with B lymphocyte signaling through interaction with Lyn kinase.


Sujet(s)
Humains , Lignée cellulaire , Herpèsvirus humain de type 8/génétique , Immunotransfert , Immunoprécipitation , Protéines membranaires/génétique , Facteurs de transcription NFATC/génétique , Phosphorylation , Liaison aux protéines , Sarcome de Kaposi/virologie , Facteur de transcription AP-1/génétique , Transfection , Protéines virales/génétique , src-Family kinases/génétique
3.
Exp. mol. med ; Exp. mol. med;: 256-264, 2006.
Article de Anglais | WPRIM | ID: wpr-96565

RÉSUMÉ

Bone is a dynamic tissue that is regulated by the activity of bone-resorbing osteoclasts and bone-forming osteoblasts. Excessive osteoclast formation causes diseases such as osteoporosis and rheumatoid arthritis. Natural substances may be useful as therapeutic drugs to prevent many diseases in humans because they avoid the many side effects of treatment with chemical compounds. Here we show that tanshinone IIA isolated from Salvia miltiorrhiza Bunge inhibits the receptor activator of NF-kappaB ligand (RANKL)-mediated osteoclast differentiation of osteoclast precursors. Tanshinone IIA suppressed the expression levels of c-Fos and NFATc1 induced by RANKL. However, retrovirus-mediated overexpression of c-Fos induced the expression of NFATc1 despite the presence of tanshinone IIA and reversed the inhibitory effect of tanshinone IIA on osteoclast differentiation. Also, the introduction of osteoclast precursors with the NFATc1 retrovirus led to osteoclast differentiation in the presence of tanshinone IIA. Our results suggest that tanshinone IIA may have a role as a therapeutic drug in the treatment of bone disease such as osteoporosis.


Sujet(s)
Souris , Mâle , Animaux , RT-PCR , Récepteur activateur du facteur nucléaire Kappa B , Ligand de RANK , Protéines proto-oncogènes c-fos/génétique , Phénanthrènes/pharmacologie , Ostéoclastes/cytologie , Facteurs de transcription NFATC/génétique , Souris de lignée ICR , Glycoprotéines membranaires/génétique , Facteur de stimulation des colonies de macrophages/pharmacologie , Immunotransfert , Expression des gènes/effets des médicaments et des substances chimiques , Régulation négative/effets des médicaments et des substances chimiques , Cellules cultivées , Différenciation cellulaire/effets des médicaments et des substances chimiques , Protéines de transport/génétique , Cellules de la moelle osseuse/cytologie
4.
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;38(3): 335-344, mar. 2005. ilus
Article de Anglais | LILACS | ID: lil-394804

RÉSUMÉ

The nuclear factor of activated T cells (NFAT) family of transcription factors has been primarily identified in immune cells; however, these proteins have been recently found to be functionally active in several other non-immune cell types. NFAT proteins are activated upon different stimuli that lead to increased intracellular calcium levels. Regardless of their widely known cytokine gene expression properties, NFATs have been shown to regulate other genes related to cell cycle progression, cell differentiation and apoptosis, revealing a broader role for these proteins in normal cell physiology. Several reports have addressed the participation of NFATs in many aspects of malignant cell transformation and tumorigenic processes. In this review, we will discuss the involvement of the different NFAT family members in the regulation of cell cycling, differentiation and tumor formation, and also its implications on oncogenesis. Better understanding the mechanisms by which NFATs regulate cell cycle and tumor-related events should be relevant for the development of rational anti-cancer therapies.


Sujet(s)
Humains , Transformation cellulaire néoplasique/métabolisme , Régulation de l'expression des gènes tumoraux , Activation des lymphocytes , Facteurs de transcription NFATC/physiologie , /métabolisme , Transformation cellulaire néoplasique/génétique , Facteurs de transcription NFATC/génétique , Facteurs de transcription NFATC/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE